For Kidneys Sake

For Kidneys' Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) This podcast series aims to provide healthcare professionals, particularly primary care professionals, with accessible insights into kidney health. Each episode offers bite-sized discussions on key topics such as chronic kidney disease management and heart failure and practical updates for improving patient care. With episodes just 15 minutes long, you can listen on your commute, during a break, or while out for a walk. Join us as we explore the latest advancements and strategies in integrated kidney care to empower clinicians and patients alike.

For Kidneys Sake is a education podcast hosted by Unknown Host, with 42 episodes on record and a Required Pod Score of 81. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts For Kidneys Sake, a education show with 42 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #41

  Think kidneys in hypertension and managing the combination

  Aug 17, 202622 minS1

  Do you have a question? Send it now... The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) Could your patient's kidneys be telling you something their blood pressure isn't? In this episode of For Kidney's Sake , Prof Jeremy Levy and Dr Andrew Frankel are joined by Prof Ian Wilkinson, President of the British and Irish Hypertension Society, to explore the close relationship between hypertension and chronic kidney disease (CKD). The discussion explains how the two conditions influence each other, why kidney assessment should form part of every hypertension diagnosis, and how clinicians can identify patients who may have secondary causes of hypertension or early kidney damage. The conversation focuses on practical steps for primary care, including the importance of measuring eGFR, urine ACR and performing urine dipstick testing as part of routine assessment. The episode also examines treatment strategies that not only lower blood pressure but protect kidney function. The speakers discuss the role of ACE inhibitors and ARBs as kidney-protective therapies, the appropriate use of thiazide diuretics in CKD, selecting suitable second-line antihypertensive agents, blood pressure targets, monitoring schedules, accurate blood pressure measurement and lifestyle interventions. Throughout, the emphasis remains on treating the whole patient rather than simply targeting a blood pressure number, with practical advice aimed at improving long-term kidney and cardiovascular outcomes. Top 5 Take aways: · Hypertension and chronic kidney disease have a two-way relationship, each can contribute to the development and progression of the other. · Every patient with hypertension should have kidney assessment including eGFR, urine ACR and urine dipstick testing. · ACE inhibitors and ARBs are kidney-protective treatments and should be optimised where appropriate, even when blood pressure is already controlled. · Thiazide diuretics remain effective in many patients with CKD and should not be avoided simply because kidney function is reduced. · Accurate blood pressure measurement , lifestyle modification and good medication adherence are essential for protecting both cardiovascular and kidney health. Resource Links: NICE GUIDELINES [NG203] chronic kidney disease: assessment and management Overview | Chronic kidney disease: assessment and management | Guidance | NICE Northwest London CKD guidelines for primary care Chronic kidney disease (nwlondonicb.nhs.uk) The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement. You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub

  ListenShow Notes
• 

  For Kidneys Sake

  A fine time for finerenone: another kidney drug that works

  Aug 3, 202617 min

  Do you have a question? Send it now... The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) Do we really need another kidney drug? Many people still see finerenone as 'just another spironolactone ', but is that really the case? In this episode of For Kidney's Sake , Prof Jeremy Levy and Dr Andrew Frankel explore why finerenone is changing the management of diabetic kidney disease and where it fits alongside ACE inhibitors, ARBs and SGLT2 inhibitors. The discussion covers the evidence behind finerenone, why patients remain at 'residual risk' despite current therapies, and how adding another treatment can further slow the progression of chronic kidney disease while reducing cardiovascular events. Jeremy and Andrew also share practical guidance on prescribing, monitoring potassium safely and overcoming the therapeutic inertia that can prevent patients from receiving effective treatments. 5 Key Takeaways Finerenone is not simply another spironolactone. Its selective mechanism and clinical trial evidence make it a distinct treatment for people with diabetic kidney disease. Many patients still have 'residual risk'. Even with ACE inhibitors, ARBs and SGLT2 inhibitors, ongoing albuminuria can signal continued kidney disease progression. Combination therapy matters. Adding finerenone to existing evidence-based treatments can further reduce the risk of kidney failure and cardiovascular events. Hyperkalaemia shouldn't be a barrier. With appropriate patient selection and routine monitoring, finerenone is straightforward to prescribe and generally well tolerated. Early optimisation is key. Identifying eligible patients during annual diabetes and CKD reviews gives clinicians the opportunity to protect kidney function before irreversible decline occurs. Resource Links: NICE GUIDELINES [NG203] chronic kidney disease: assessment and management Overview | Chronic kidney disease: assessment and management | Guidance | NICE Northwest London CKD guidelines for primary care Chronic kidney disease (nwlondonicb.nhs.uk) The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement. You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub

  ListenShow Notes
• 

  Episode #39

  It’s all Relative: When Kidney Disease Runs in the Family

  Jul 20, 202623 minS1

  Do you have a question? Send it now... The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) Is Kidney Disease Hiding in the Family? Could a patient’s kidney disease have a genetic cause and what clues might we be missing? Genetic kidney conditions are more common than many clinicians realise, and spotting the signs early can change not only one patient’s care, but potentially the care of an entire family. In this episode, Andrew and Jeremy are joined by renal genetics expert Dr Mel Chan to unpack the key genetic kidney conditions clinicians need on their radar. From polycystic kidney disease and Alport syndrome to congenital abnormalities and inherited kidney stones, they explore the red flags that should make you think genetics and why asking the right questions, making an early referral and securing a diagnosis can have a lasting impact on treatment, prognosis and family screening. Key Takeaways: Think family. Kidney disease, haematuria, stones, dialysis, transplantation or early deaths in relatives could be an important clue. Spot the red flags. Young age, unexplained CKD, early hypertension, hearing loss, recurrent stones or congenital abnormalities should make you think genetic. Suspect it? Refer it. You don’t need to be a genetics expert, recognising when specialist assessment is needed is what matters. A diagnosis can change the story. Genetic testing can sharpen prognosis, guide treatment and help identify relatives who may also be at risk. Keep patients on the radar. Childhood kidney problems don’t necessarily stay in childhood. Long-term follow-up can help prevent patients from returning years later with advanced CKD. Resource Links: NICE GUIDELINES [NG203] chronic kidney disease: assessment and management Overview | Chronic kidney disease: assessment and management | Guidance | NICE Northwest London CKD guidelines for primary care Chronic kidney disease (nwlondonicb.nhs.uk) The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement. You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub

  ListenShow Notes
• 

  Episode #38

  A Century of Creatinine and the Endless Search for Accuracy

  Jun 29, 202620 minS1

  Do you have a question? Send it now... This week on For Kidneys Sake , Prof Jeremy Levy and Dr Andrew Frankel celebrate an unlikely centenary: 100 years since creatinine was first recognised as a marker of kidney function. From the early days of serum creatinine and the Cockcroft-Gault formula to today’s eGFR reporting, the duo unpack how kidney function testing evolved and why the numbers we rely on still come with important caveats. The conversation explores why muscle mass can dramatically distort creatinine-based kidney estimates, when cystatin C offers a better alternative, and why gold-standard nuclear medicine tests remain impractical for routine care. Along the way, they tackle common misconceptions around eGFR, explain why urine ACR tells a different story entirely, and remind listeners that numbers should never replace clinical judgement. A witty, practical, and surprisingly celebratory deep dive into the science behind every kidney health check. Top 5 Takeaways 1. Creatinine has been used for 100 years — Serum creatinine was recognised as a marker of kidney function in 1926, making 2026 the centenary year of one of medicine’s most widely used blood tests. 2. eGFR is helpful — but imperfect — eGFR improves on creatinine alone by incorporating age and sex into mathematical formulas, but it still struggles in people with unusually high or low muscle mass. 3. Muscle mass matters more than many realise — A muscular person may appear to have “worse kidneys” on paper, while frail patients with low muscle mass can have deceptively normal creatinine levels despite significant kidney disease. 4. Cystatin C is an underused alternative — Unlike creatinine, cystatin C is not heavily influenced by muscle mass and can provide a more accurate estimate of kidney function in selected patients. 5. Kidney health is more than eGFR — Urine ACR measures kidney damage rather than filtration and can be abnormal even when kidney function appears normal. Both tests matter. The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement. You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub

  ListenShow Notes
• 

  For Kidneys Sake

  Wee Need to Talk About UTIs

  Jun 15, 202623 minS0

  <p>Do you have a question? Send it now...</p><p><b>The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS)</b></p><p><b>How confident are you that the patient in front of you really has a urinary tract infection?</b></p><p>In this episode of For Kidneys Sake, consultant nephrologists Jeremy Levy and Andrew Frankel tackle one of the most common yet surprisingly complex conditions seen in primary care: urinary tract infections (UTIs). They explore why diagnosing a UTI is...

  ListenShow Notes

Recent guests on For Kidneys Sake. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.